



U.S.-U.A.E. Business Council  
[usuaebusiness.org](http://usuaebusiness.org)

CORPORATE SPOTLIGHT  
HEALTH SERIES

# DANA-FARBER CANCER INSTITUTE

OCT 2021



Dana-Farber  
Cancer Institute

YAWKEY CENTER  
FOR CANCER CARE

450 BROOKLINE AVENUE

BUSINESS COUNCIL REPORT





**Dana-Farber**  
Cancer Institute

MA BOSTON



**U.S. NEWS & WORLD REPORT**  
**RANKED #2 IN U.S FOR**  
**PEDIATRIC CANCER & #4 FOR**  
**ADULT CANCER**



**NEWSWEEK**  
**RANKED #3 IN WORLD'S BEST**  
**SPECIALIZED HOSPITALS**



**CLINICAL TRIALS**  
**1,100+**

## OVERVIEW

For over 70 years, Dana-Farber Cancer Institute has had one goal: to reduce the suffering caused by cancer through advanced clinical care and scientific research. Dana-Farber is committed to providing multidisciplinary, compassionate, and collaborative care that puts patients and their families at the center. Care is provided by teams of specialists organized around combating specific types of cancer, providing easy and direct access for patients. As a principal teaching affiliate of Harvard Medical School, Dana-Farber attracts many of the best and brightest physicians and researchers in the world to share in this mission.

Dana-Farber is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), a National Cancer Institute (NCI)-designated Comprehensive Cancer Center. Dana-Farber has the most highly cited research of any leading U.S. cancer center and is the top recipient of NCI funding. Over the last ten years, approximately 25% of all FDA-approved cancer drugs in the U.S. were in part developed with Dana-Farber Cancer Institute.

Dana-Farber is a Magnet® organization, a designation that recognizes the Institute's quality patient care, nursing excellence and innovations in professional nursing practice. Dana-Farber's expert clinical and support services teams strive to provide patients and their families with an excellent patient-centered experience and to maintain quality of life during and after treatment. When surveyed, over 96% of Dana-Farber patients were satisfied with the care they received at Dana-Farber, and 96.9% said they would recommend Dana-Farber.

## CLINICAL PARTNERSHIPS

Dana Farber is the only hospital nationwide with a top 5 U.S. News & World Report "Best Hospitals" ranking in both adult and pediatric cancer care.

Dana-Farber Brigham Cancer Center brings together specialists from Dana-Farber Cancer Institute and Brigham and Women's Hospital to treat adults with all types of cancer. The multidisciplinary teams include medical, radiation, and surgical oncologists along with radiology and pathology subspecialists in each type of cancer. They offer the latest treatments, many of which were pioneered at Dana-Farber, along with clinical trials for promising new therapies.

Dana-Farber/Boston Children's Cancer and Blood Disorders Center offers the combined expertise of Dana-Farber Cancer Institute and Boston Children's Hospital, the top ranked pediatric hospital in the nation by the U.S News & World Report, to provide seamless, integrated care for children with all types of cancer and blood disorders – including the rarest and most complex cases.

## ADULT TREATMENT CENTERS

At Dana-Farber, care for patients is provided in dedicated treatment centers by teams of experts who specialize in that type of cancer.



**BREAST CANCER**



**CANCER GENETICS & PREVENTION**



**CUTANEOUS (SKIN) CANCER**



**GASTROINTESTINAL CANCER**



**GENITOURINARY CANCER**



**GYNECOLOGIC CANCER**



**HEAD & NECK CANCER**



**HEMATOLOGIC ONCOLOGY**



**HEMATOLOGY**



**MELANOMA**



**NEURO-ONCOLOGY**



**SARCOMA & BONE CANCER**



**THORACIC (LUNG) CANCER**

### CLINICAL SERVICES & SPECIALTY CENTERS:

- [Adolescent and Young Adult Neuro-Oncology Program](#)
- [Center for Cancer Therapeutic Innovation](#)
- [Center for Immuno-Oncology](#)
- [Fertility Preservation \(Oncofertility\) Programs](#)
- [Oral Medicine and Oral Oncology](#)
- [Palliative Care](#)
- [Psychosocial Oncology](#)
- [Stem Cell Transplantation and Cellular Therapies](#)
- [Survivorship Program](#)

## PEDIATRIC TREATMENT CENTERS INCLUDE:



**SOLID TUMORS**



**BLOOD DISORDERS**



**HEMATOLOGIC MALIGNANCIES**



**NEURO-ONCOLOGY**



**STEM CELL TRANSPLANT**



**U.S. NEWS & WORLD REPORT**  
**RANKED #2 IN U.S FOR**  
**PEDIATRIC CANCER & #4 FOR**  
**ADULT CANCER**




**NEWSWEEK**  
**RANKED #3 IN WORLD'S BEST**  
**SPECIALIZED HOSPITALS**



**CLINICAL TRIALS**  
**1,100+**

## BRIDGING RESEARCH & CARE

RESEARCH INFORMS CARE << >> CARE INFORMS RESEARCH



Dana-Farber has a broad history of bridging cancer research and care. It started more than 70 years ago when Dr. Sidney Farber pioneered chemotherapy. It continues today with Dr. Gordon Freeman, who discovered the PD-L1 pathway which revolutionized the science of immunotherapy by making cancer cells more vulnerable to attack by the body's immune system. In 2019, Dana-Farber's Dr. William G. Kaelin received the Nobel Prize in Physiology or Medicine. Dr. Kaelin's work has enabled a whole class of oxygen-regulating drugs that can cut off the oxygen supply to tumor cells. His work is being applied beyond cancer in patients with macular degeneration, heart disease and anemia.

Dana-Farber's commitment to fighting cancer with equal parts research and patient care is supported by a broad and deep array of resources. These resources are organized into several specialized departments, centers, and programs that have evolved in response to changes in perceived needs and the availability of new technologies.

**Dana-Farber is composed of:**

- 19 comprehensive clinical divisions and programs
- Three interdisciplinary basic science/research divisions
- Over 70 independent research laboratories
- Community-based research program
- Harvard Medical School clinical fellowship program

## PRECISION CANCER MEDICINE

Dana-Farber is home to one of the nation's most comprehensive precision cancer medicine research initiatives, having completed more than 50,000 genetic profiles of patients' tumors and adding about 400 each month to the database.

Their clinicians use specialized tests to create a precise "tumor profile" of genetic changes for each patient's cancer, making it possible to identify the most important mutations. Results from these tests can help in the selection of specific therapeutic agents to precisely treat each individual's cancer.

## INTERNATIONAL COLLABORATION

As part of its global mission, Dana-Farber offers a broad range of advisory services to international organizations, including existing healthcare systems and new hospital development projects. Dana-Farber has active international collaborations in South America, China and is actively exploring opportunities in the GCC. Advisory, education, and training services are provided by the same expert team of administrators and clinicians who manage hospital operations and take care of cancer patients back in Boston. Advisory education and training services are customized to meet the individual needs of each organization, and support external institutions through onsite visits and rotations, remote video conferences, and leadership meetings in Boston.

**Dana-Farber International Advisory services include:**

- **Consultation on Hospital Operations and Management**
  - Hospital and facilities design and planning
  - Hospital infrastructure and governance planning
  - Multidisciplinary care model development
  - Peer-to-peer mentoring for senior leaders
  - Senior leadership recruitment guidance
  - Clinical operations
  - Quality and Patient Safety program development
- **Clinical Program Development**
  - Subspecialty cancer services
  - Survivorship
  - Palliative Care
  - Clinical Genetics
  - Integrative Medicine
- **Research Program Development**
  - Operations and infrastructure planning
  - Clinical trials training
- **Clinician Education & Training**  
(MDs, RNs, Pharmacists, and ancillary clinical staff)
  - Observerships (in person at DFCI and remotely)
  - Simulation-based training
  - Symposia
  - Digital training modules
- **Telemedicine Services**
  - Formal remote 2nd opinions
  - Virtual Multidisciplinary Tumor Boards





**U.S. NEWS & WORLD REPORT**  
**RANKED #2 IN U.S FOR**  
**PEDIATRIC CANCER & #4 FOR**  
**ADULT CANCER**



**NEWSWEEK**  
**RANKED #3 IN WORLD'S BEST**  
**SPECIALIZED HOSPITALS**



**CLINICAL TRIALS**  
**1,100+**

## DANA-FARBER PATHWAYS IN ONCOLOGY

Dana-Farber Pathways is an electronic roadmap of the best treatments currently available for each type of cancer and for every stage of the disease. **Oncology Pathways**, developed in collaboration with Royal Philips, provides organizations and clinicians around the world access to the expertise of more than 300 oncologists, scientists and pharmacy experts at Dana-Farber. The solution will help oncologists efficiently reach the most appropriate cancer treatments for patients, based on a unified view of the patient across diagnostic modalities. With Dana-Farber's Clinical Pathways, oncologists get recommendations for specific therapies – and clinical trials – matched to patient characteristics, such as specific gene mutations. Recommendations are based on the latest scientific insights and are continuously updated, enabling treatment selection that is more personalized and standardized at the same time. The solution delivers data-driven guidance to help the broader cancer care team more easily navigate the increasing complexities of cancer care diagnostics and treatment options.

## LEADERSHIP

### Laurie H. Glimcher | MD

President & Chief Executive Officer of the Dana-Farber Cancer Institute  
Director, Dana-Farber/Harvard Cancer Center  
Richard & Susan Smith Professor of Medicine, Harvard Medical School

*“ Cancer knows no borders. People everywhere should have access to the best possible cancer care and latest therapies. Through innovative international collaborations, we can extend the reach of our world-class cancer care to support patients in the U.A.E. and across the globe. ”*

- Dr. Laurie H. Glimcher

### William C. Hahn | MD | PhD

Executive Vice President & Chief Operating Officer, Dana-Farber Cancer Institute  
Chair, Executive Committee for Research  
William Rosenberg Professor of Medicine  
Institute Member of the Broad Institute of MIT & Harvard

## CONTACT INFO

### International Strategic Initiatives

Email: [internationalinitiatives@dfci.harvard.edu](mailto:internationalinitiatives@dfci.harvard.edu)

### Katya Losk

Director, International Strategic Initiatives  
Email: [Katya\\_Losk@dfci.harvard.edu](mailto:Katya_Losk@dfci.harvard.edu)

### Basel Tarab

Senior Manager, International Strategic Initiatives  
Email: [Basel\\_Tarab@dfci.harvard.edu](mailto:Basel_Tarab@dfci.harvard.edu)

### Adriana Perilla

Senior Program Manager, International Strategic Initiatives  
Email: [Adriana\\_PerillaGlen@dfci.harvard.edu](mailto:Adriana_PerillaGlen@dfci.harvard.edu)

### Megan Valenza

Program Manager, International Strategic Initiatives  
Email: [Megan\\_Valenza@dfci.harvard.edu](mailto:Megan_Valenza@dfci.harvard.edu)

## WEBSITES

DANA-FARBER CANCER INSTITUTE  
<https://dana-farber.org>



## CLINICAL ADVANCES

Learn more about Dana-Farber's clinical advances here  
<https://physicianresources.dana-farber.org>



## U.S.-U.A.E. PARTNERSHIPS

Dana-Farber Cancer Institute has provided the most advanced treatment available to hundreds of adult and pediatric Emirati patients for many years. A dedicated international patient coordination team, including Arabic-speaking staff, coordinate all aspects of care for adult and pediatric patients and their families.

Dana-Farber has actively participated in Arab Health and Dana-Farber physicians have been invited to share their innovative research and provide educational talks in the UAE.



U.S.-U.A.E. Business Council  
[usuaebusiness.org](http://usuaebusiness.org)

@USUAEBizCouncil